2021 Inova Cardiovascular Symposium - Online Course

Activity Details

$20.00
Registration
6/8/2021
6/7/2022
Any time

Contact Information

352-733-0064
720 SW 2nd Ave., Suite 575
Gainesville, Florida 32601

View Faculty Listing (Links to an external site.)

View Faculty Disclosure (Links to an external site.)

Release Date: June 8, 2021
Expiration Date: June 7, 2022

Target Audience: Cardiologists, cardiovascular clinicians, cardiac surgeons, vascular surgeons, internists, hospitalists, primary care physicians, fellows and residents in training, advanced practice nurses, nurses in cardiology and other medical professionals interested in cardiovascular medicine.

Learning Objectives:

As a result of participation in this activity, participants should be able to:

  1. Employ evidence-based management strategies for the evaluation and treatment of heart failure.
  2. Describe patient selection criteria for Trans-Aortic Valve Replacement (TAVR).
  3. List the unique risk factors and manifestations of heart disease in women.

Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and Inova Heart and Vascular Institute. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resource(s) for further study:

  1. Bhatt AS, Abraham WT, Lindenfeld J, Bristow M, Carson PE, Felker GM, Fonarow GC, Greene SJ, Psotka MA, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Wittes J, Fiuzat M, O'Connor CM, Butler J. Treatment of HF in an Era of Multiple Therapies: Statement from the HF Collaboratory. JACC Heart Fail. 2020 Dec 9: S2213-1779(20)30592-8.

 

Commercial Support: 

This CME activity is supported by an educational grants from Abbott Laboratories, Biosense Webster, Inc, Chiesi USA, Inc, Cytokinetics, Medtronic, Merck, Novartis, and Zoll.

This CME activity is supported by an exhibits from Abbott Laboratories, Abiomed, Amgen, AstraZeneca, BioTel Heart, Boston Scientific, CVRx, Edwards Lifesciences, Esperion Theapeutics, Inc, Gore & Associates, Impulse Dynamics, Janssen Pharmaceutical, Medtronic, and Pfizer. View the virtual exhibit hall (Links to an external site.)

Section #: 1510, 2220